Risk factors for MDS/AML and death from sepsis in patients with SCN in the SCNIR
. | . | MDS/AML . | . | Death from sepsis . | . | ||
|---|---|---|---|---|---|---|---|
| Factor* . | Group . | RH (95% CI)† . | P‡ . | RH (95% CI)† . | P . | ||
| G-CSF at 6 mo | |||||||
| 6 μg/kg/d or more vs less than 6 μg/kg/d | 2 | 2.5 (1.2-5.2) | .008 | 2.0 (0.7-5.5) | .180 | ||
| 8 μg/kg/d or more vs less than 8 μg/kg/d | 2 | 1.9 (1.0-3.7) | .036 | 2.9 (1.0-8.1) | .029 | ||
| Per doubling§ | 2 | 1.22 (1.03-1.44) | .024 | 1.31 (1.02-1.69) | .039 | ||
| ANC at 6-18 mo | |||||||
| Less than 2188/μL vs at least 2188/μL | 5 | 2.3 (1.2-4.7) | .016 | 3.4 (0.9-12.9) | .056 | ||
| Per halving¶ | 5 | 1.25 (1.00-1.56) | .058 | 1.55 (1.17-2.05) | .006 | ||
| G-CSF at 6 mo, and ANC at 6-18 mo | |||||||
| A: 8 μg/kg/d or more, and ANC less than 2188/μL | 5 | 4.5 (1.5-13.4) | .008 | 3.8 (0.79-18.3) | .094 | ||
| B: Less than 8 μg/kg/d, and ANC less than 2188/μL | 5 | 1.7 (0.5-6.4) | .422 | 0.6 (0.05-6.9) | .689 | ||
| C: 8 μg/kg/d or more and ANC of at least 2188/μL | 5 | 1.7 (0.5-5.5) | .402 | 0.5 (0.04-5.1) | .525 | ||
| D: Less than 8 μg/kg/d, and ANC of at least 2188/μL | 5 | 1.0 (Referent) | NA | 1.0 (Referent) | NA | ||
| A: 8 μg/kg/d or more and ANC below 2188/μL, vs B-D: other | 5 | 3.1 (1.5-6.1) | .002 | 5.6 (1.7-18.7) | .004 | ||
| ANC before treatment | |||||||
| Less than 138 cells/μL vs 138 cells/μL or more | 3 | 0.9 (0.5-1.6) | .627 | 2.3 (0.75-7.25) | .123 | ||
| Per halving¶ | 3 | 0.96 (0.79-1.16) | .648 | 1.27 (0.92-1.74) | .145 | ||
. | . | MDS/AML . | . | Death from sepsis . | . | ||
|---|---|---|---|---|---|---|---|
| Factor* . | Group . | RH (95% CI)† . | P‡ . | RH (95% CI)† . | P . | ||
| G-CSF at 6 mo | |||||||
| 6 μg/kg/d or more vs less than 6 μg/kg/d | 2 | 2.5 (1.2-5.2) | .008 | 2.0 (0.7-5.5) | .180 | ||
| 8 μg/kg/d or more vs less than 8 μg/kg/d | 2 | 1.9 (1.0-3.7) | .036 | 2.9 (1.0-8.1) | .029 | ||
| Per doubling§ | 2 | 1.22 (1.03-1.44) | .024 | 1.31 (1.02-1.69) | .039 | ||
| ANC at 6-18 mo | |||||||
| Less than 2188/μL vs at least 2188/μL | 5 | 2.3 (1.2-4.7) | .016 | 3.4 (0.9-12.9) | .056 | ||
| Per halving¶ | 5 | 1.25 (1.00-1.56) | .058 | 1.55 (1.17-2.05) | .006 | ||
| G-CSF at 6 mo, and ANC at 6-18 mo | |||||||
| A: 8 μg/kg/d or more, and ANC less than 2188/μL | 5 | 4.5 (1.5-13.4) | .008 | 3.8 (0.79-18.3) | .094 | ||
| B: Less than 8 μg/kg/d, and ANC less than 2188/μL | 5 | 1.7 (0.5-6.4) | .422 | 0.6 (0.05-6.9) | .689 | ||
| C: 8 μg/kg/d or more and ANC of at least 2188/μL | 5 | 1.7 (0.5-5.5) | .402 | 0.5 (0.04-5.1) | .525 | ||
| D: Less than 8 μg/kg/d, and ANC of at least 2188/μL | 5 | 1.0 (Referent) | NA | 1.0 (Referent) | NA | ||
| A: 8 μg/kg/d or more and ANC below 2188/μL, vs B-D: other | 5 | 3.1 (1.5-6.1) | .002 | 5.6 (1.7-18.7) | .004 | ||
| ANC before treatment | |||||||
| Less than 138 cells/μL vs 138 cells/μL or more | 3 | 0.9 (0.5-1.6) | .627 | 2.3 (0.75-7.25) | .123 | ||
| Per halving¶ | 3 | 0.96 (0.79-1.16) | .648 | 1.27 (0.92-1.74) | .145 | ||
RH indicates relative hazard; NA, not available.
See Table 1 for a summary of follow-up data by group.
Cut-points for dose of G-CSF and ANC values were defined by the group-specific medians.
RHs and 95% CIs estimated using Cox proportional hazards models.
P values for likelihood ratio tests (factors G-CSF at 6 mo; ANC at 6-18 mo; and ANC before treatment) or Wald tests (contrasting levels in factor G-CSF at 6 mo and ANC at 6-18 mo).
A model with log2 G-CSF dose was fitted; the RH per doubling is the RH corresponding to a 1-unit increase of G-CSF dose on the log2 scale or a doubling of a G-CSF dose on the absolute scale.
Models with log2 ANC values were fitted; the RH per halving is the RH corresponding to a 1-unit decrease of G-CSF dose on the log2 scale or a halving of G-CSF dose on the absolute scale.